Genetics of alcohol-related hepatocellular carcinoma - its role in risk prediction

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, with increasing incidence worldwide. Alcohol-related cirrhosis (AC) accounts for 30% of the global incidence of HCC and HCC-related deaths. With the decline of hepatitis C virus (HCV) and decreasing HCV-related HCC, AC will soon become the leading cause of HCC. Excess alcohol consumption (> 80 g per day for > 10 years) increases the risk of HCC by 5-fold. However, only up to 35% of excessive drinkers develop cirrhosis and its associated HCC risk. Individual variation in susceptibility to HCC is known, but there is limited information to predict who among the patients is at high risk of progressing to HCC. Clinical risk factors for HCC include male gender, older age, severity of cirrhosis, obesity and presence of type 2 diabetes. In addition to ethnic variability in HCC risk, genetic variants are known to alter the risk of alcohol-related HCC. For example, single nucleotide polymorphisms in PNPLA3 (rs738409, C>G) and TM6SF2 (rs58542926, C>T) increase the risk of AC-related HCC, whereas HSD17B13 (T>A) reduces the risk for HCC. Studies have also confirmed PNPLA3 and TM6SF2 to be independent risk factors for AC-related (but not HCV-related) HCC. Combining genetic risk factors with phenotypic/clinical risk factors has been explored for stratification of patients for HCC development. Risk allele rs378409-G in PNPLA3 when combined with phenotypic/clinical risk factors (BMI, age, sex) has enabled HCC risk stratification of AC patients into low-, intermediate- and high-risk subgroups. Similarly, a combination of the two genetic variants PNPLA3-G and TM6SF2-T has been independently associated with risk of HCC onset. Using a polygenic risk score approach of incorporating several genetic variants, prognostic performance of polygenic risk score that included PNPLA3 rs378409 and TM6SF2 rs58542926 improved HCC prediction better than with either variant alone. Incorporating new variants and risk factors has the potential to build better algorithms/models to predict onset, early diagnosis and treatments for AC-related HCC. However, clinical usefulness of these approaches is yet to be determined.

Keywords

Alcohol-related cirrhosis / PNPLA3 / HSD17B13 / TM6SF2 / risk prediction

References

[1] Villanueva A.Hepatocellular carcinoma..Engl J Med2019;380:1450-62

[2] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[3] Forner A,Bruix J.Hepatocellular carcinoma..Lancet2018;391:1301-14

[4] Yang JD,Gores GJ,Plymoth A.A global view of hepatocellular carcinoma: trends, risk, prevention and management..Nat Rev Gastroenterol Hepatol2019;16:589-604 PMCID:PMC6813818

[5] El-Serag HB,Everhart JE.Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma..Gastroenterology2004;126:460-8

[6] N’Kontchou G,Htar MTT,Costentin L.Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis..Clin Gastroenterol Hepatol2006;4:1062-8

[7] Zaman SN,Johnson RD,Johnson PJ.Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients..Lancet1985;1:1357-60

[8] Yu MW,Liaw YF,Lee SD.Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives..J Natl Cancer Inst2000;92:1159-64

[9] Hemminki K.Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden..Gut2003;52:592-6 PMCID:PMC1773609

[10] Rich NE,Odewole M,Parikh ND.Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma..Clin Gastroenterol Hepatol2019;17:551-9.e1 PMCID:PMC6274621

[11] Herbst DA.Risk factors for hepatocellular carcinoma..Clin Liver Dis2012;1:180-2

[12] Stickel F,Hahn EG.Cocarcinogenic effects of alcohol in hepatocarcinogenesis..Gut2002;51:132-9 PMCID:PMC1773267

[13] Ganne-Carrié N,Bourcier V,Perarnau JM.Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis..J Hepatol2018;69:1274-83

[14] Morgan TR,Jamal MM.Alcohol and hepatocellular carcinoma..Gastroenterology2004;127:S87-96

[15] Roerecke M,Hasan OSM,Cruz M.Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis..Am J Gastroenterol2019;114:1574-86 PMCID:PMC6776700

[16] Grewal P.Liver cancer and alcohol..Clin Liver Dis2012;16:839-50

[17] Ganne-Carrié N.Hepatocellular carcinoma in the setting of alcohol-related liver disease..J Hepatol2019;70:284-93

[18] Akinyemiju T,Ahmed M,Alemayohu MA.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015..JAMA Oncol2017;3:1683-91 PMCID:PMC5824275

[19] Heckley GA,Asamoah BO.How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature..BMC Cancer2011;11:446 PMCID:PMC3229519

[20] Gao B.Alcoholic liver disease: pathogenesis and new therapeutic targets..Gastroenterology2011;141:1572-85 PMCID:PMC3214974

[21] Jean-Frédéric B,Marie-Quitterie P,Caroline B.Diabetes, HBV infection and smoking are independent risk factors for developing hepatocellular carcinoma on non-fibrotic liver in the NoFLIC French multicenter case-control study..Hepatology2015;62:276A

[22] Costentin CE,Lahmek P,Pariente A.Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective, nationwide study..Cancer2018;124:1964-72

[23] Bucci L,Camelli V,Farinati F.Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome..Aliment Pharmacol Ther2016;43:385-99

[24] Kumar R,Kam JW,Tan CK.Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma..Clin Mol Hepatol2020;26:196-208 PMCID:PMC7160352

[25] EASLEASL Clinical Practice Guidelines: management of hepatocellular carcinoma..J Hepatol2018;69:182-236

[26] Marrero JA,Sirlin CB,Finn RS.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases..Hepatology2018;68:723-50

[27] Andersson KL,Goldie SJ.Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis..Clin Gastroenterol Hepatol2008;6:1418-24 PMCID:PMC4340842

[28] Bolondi L,Siringo S,Casali A.Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis..Gut2001;48:251-9 PMCID:PMC1728189

[29] Singal AG,Nahon P.Epidemiology and surveillance for hepatocellular carcinoma: new trends..J Hepatol2020;72:250-61 PMCID:PMC6986771

[30] Singal AG,Gupta S,Halm EA.Failure rates in the hepatocellular carcinoma surveillance process..Cancer Prev Res (Phila)2012;5:1124-30 PMCID:PMC3435471

[31] Thursz M,Lackner C,Moreno C.EASL Clinical Practice Guidelines: Management of alcohol-related liver disease..J Hepatol2018;69:154-81

[32] Teschke R.Alcoholic liver disease: alcohol metabolism, cascade of molecular mechanisms, cellular targets, and clinical aspects..Biomedicines2018;6:106 PMCID:PMC6316574

[33] Seitz HK.Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress..Biol Chem2006;387:349-60

[34] Stickel F.Genetic determinants of alcoholic liver disease..Gut2012;61:150-9

[35] Stickel F.The role of genetic polymorphisms in alcoholic liver disease..Alcohol Alcohol2006;41:209-24

[36] Homann N,Konig IR,Junghanns K.Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers..Int J Cancer2006;118:1998-2002

[37] Seitz HK.Molecular mechanisms of alcohol mediated carcinogenesis..Nat Rev2007;7:599-612

[38] Dasgupta A.Genetic polymorphisms of alcohol metabolizing enzymes associated with protection from or increased risk of alcohol abuse..Alcohol, Drugs, Genes and the Clinical Laboratory2017;107-16

[39] Abul-Husn NS,Li AH,Schurmann C.A protein-truncating HSD17B13 variant and protection from chronic liver disease..Engl J Med2018;378:1096-106

[40] Buch S,Trepo E,Herrmann A.A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis..Nat Genet2015;47:1443-8

[41] Tian C,Kershenobich D,Hinds DA.Variant in PNPLA3 is associated with alcoholic liver disease..Nat Genet2010;42:21-3

[42] Trepo E,Ganne-Carrie N,Gustot T.PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis..Hepatology2012;55:1307-8

[43] Salameh H,Erwin A,Nischalke HD.PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease..Am J Gastroenterol2015;110:846-56

[44] Falleti E,Cmet S,Toniutto P.PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis..Dig Liver Dis2016;48:69-75

[45] Seth D,Haber PS.Patatin-like phospholipase domain containing 3: a case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease..Hepatology2010;51:1463-5

[46] Trépo E,Bontempi G,Falleti E.Association between the PNPLA3 (rs738409 C\textgreaterG) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data..Hepatology2014;59:

[47] Chen JH,Lv WB,Chang W.Effects of interactions between environmental factors and KIF1B genetic variants on the risk of hepatocellular carcinoma in a Chinese cohort..World J Gastroenterol2016;22:4183-90 PMCID:PMC4837435

[48] Nahon P,Guyot E,Sutton A.O054 TM6SF2-T and PNPLA3-G genetic variants co-modulate the risk of hepatocellular carcinoma in caucasian patients with alcoholic cirrhosis. Inter-cohort validation in 1068 patients..J Hepatol2015;62:S218-9

[49] Chambers JC,Sehmi J,Wass MN.Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma..Nat Genet2011;43:1131-8 PMCID:PMC3482372

[50] Stickel F,Buch S,Silva I.Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers..Hepatology2019;epub ahead of print. doi: 10.1002/hep.30996

[51] Thursz M,Mathurin P,Shah VH.Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study..J Hepatol2019;70:521-30

[52] Yang J,Nahon P,Moreno C.PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases..Int J Cancer2019;144:533-44

[53] Guyot E,Rufat P,Mansouri A.PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis..J Hepatol2013;58:312-8

[54] Kerr TA,Davidson NO.MicroRNAs and liver disease..Transl Res2011;157:241-52 PMCID:PMC3063952

[55] Xu RH,Krawczyk M,Luo H.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma..Nat Mater2017;16:1155-61

[56] Yu JH,Jin YJ,Jang JW.Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir..Eur J Gastroenterol Hepatol2019;31:865-72

[57] Whitfield JB,Cordell HJ,Masson S.Can genotyping predict risk of alcohol-related cirrhosis in high-risk drinkers?.Hepatology2019;70:171A-2

[58] Anstee QM.The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2..Semin Liver Dis2015;35:270-90

[59] Anstee QM,Day CP.Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease..Gastroenterology2016;150:1728-44.e7

[60] Torkamani A,Topol EJ.The personal and clinical utility of polygenic risk scores..Nat Rev Genet2018;19:581-90

[61] Maas P,Joshi AD,Gaudet MM.Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the United States..JAMA Oncol2016;2:1295-302 PMCID:PMC5719876

[62] Lee A,Wilcox AN,Carver T.BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors..Genet Med2019;21:1708-18 PMCID:PMC6687499

[63] Senkus E,Ohno S,Poortmans P.Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up..Ann Oncol2015;26:v8-30

[64] Stickel F,Nischalke HD,Gotthardt D.Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis..Am J Gastroenterol2018;113:1475-83

[65] Scaggiante B,Pozzato G,Farra R.Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials..World J Gastroenterol2014;20:1268-88 PMCID:PMC3921509

[66] Shang S,Ge S,Rosen HR.Identification of osteopontin as a novel marker for early hepatocellular carcinoma..Hepatology2011;483-90 PMCID:PMC3914762

[67] Sieghart W,Schmid K,König F.Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria..J Hepatol2011;54:89-97

[68] Zhou SL,Hu ZQ,Luo YJ.Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence..J Hepatol2019;71:1152-63

[69] Niu ZS,Wang WH.Genetic alterations in hepatocellular carcinoma: an update..World J Gastroenterol2016;22:9069-95 PMCID:PMC5107590

[70] Ye QH,Forgues M,Kim JW.Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning..Nat Med2003;9:416-23

[71] Wahid B,Rafiqe S.New insights into the epigenetics of hepatocellular carcinoma..Biomed Res Int2017;2017:1609575 PMCID:PMC5376429

[72] Toh TB,Chow EK.Epigenetics of hepatocellular carcinoma..Clin Trans Med2019;8:13 PMCID:PMC6500786

[73] Lozano-Rosas MG,Aparicio-Cadena AR,Sánchez VC.Mitoepigenetics and hepatocellular carcinoma..Hepatoma Res2018;4:19

[74] Méndez-Sánchez N,Vera-Barajas A,Scarpellini E.The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer..Hepatoma Res2020;6:5 PMCID:PMC7313221

[75] Neuman MG,French SW,Tsukamoto H.Alcoholic-hepatitis, links to brain and microbiome: mechanisms, clinical and experimental research..Biomedicines2020;8:63 PMCID:PMC7148515

[76] Llovet JM,Pikarsky E,Schwartz M.Hepatocellular carcinoma..Nat Rev Dis Primers2016;2:16018

[77] Sia D,Martinez-Quetglas I,Villacorta-Martin C.Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features..Gastroenterology2017;153:812-26

[78] Wheelar DA.Comprehensive and integrative genomic characterization of hepatocellular carcinoma..Cell2017;169:1327-41.e23 PMCID:PMC5680778

[79] Calderaro J,Imbeaud S,Letouze E.Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification..J Hepatol2017;67:727-38

[80] Harding JJ,Armenia J,Albano M.Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies..Clin Cancer Res2019;25:2116-26 PMCID:PMC6689131

[81] Theise ND.Histopathology of alcoholic liver disease..Clin Liver Dis2013;2:64-7 PMCID:PMC6448621

[82] Lackner C.Fibrosis and alcohol-related liver disease..J Hepatol2019;70:294-304

[83] Ganne-Carrie N,Bourcier V,Marcellin P.Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)..Hepatology2016;64:1136-47

[84] Wong VW.Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?.J Hepatol2015;63:722-32

[85] Heimbach JK,Finn RS,Abecassis MM.AASLD guidelines for the treatment of hepatocellular carcinoma..Hepatology2018;67:358-80

[86] Fujiwara N,Goossens N.Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine..J Hepatol2018;68:526-49 PMCID:PMC5818315

[87] Kraft P,Cornelis MC,Hayes RB.Beyond odds ratios--communicating disease risk based on genetic profiles..Nat Rev Genet2009;10:264-9

[88] Buniello A,Cerezo M,Hayhurst J.The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019..Nucleic Acids Res2019;47:D1005-12 PMCID:PMC6323933

[89] Sugrue LP.What are polygenic scores and why are they important?.JAMA2019;321:1820

[90] Wojcik GL,Nishimura KK,Haessler J.Genetic analyses of diverse populations improves discovery for complex traits..Nature2019;570:514-8 PMCID:PMC6785182

[91] Nakagawa S,Song WM,Ghoshal S.Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition..Cancer Cell2016;30:879-90 PMCID:PMC5161110

[92] DiMartini A,Dew MA,Fitzgerald MG.Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease..Liver Transpl2006;12:813-20

[93] Stickel F,Hampe J.The genetics of alcohol dependence and alcohol-related liver disease..J Hepatol2017;66:195-211

[94] Bjornsson E,Rydell A,Eriksson C.Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism..Scand J Gastroenterol2005;40:206-16

[95] Im GY,Lucey MR.Liver transplantation for alcoholic hepatitis..J Hepatol2019;70:328-34

[96] Hunter DJ.Has the genome granted our wish yet?.Engl J Med2019;380:2391-3

[97] Schork AJ,Schork NJ.Genetic risks and clinical rewards..Nat Genet2018;50:1210-1 PMCID:PMC6383764